Provexis (PXS) Competitors GBX 0.62 +0.05 (+8.20%) As of 04/30/2025 12:22 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsBuy This Stock PXS vs. ALK, CLCO, ICON, PAA, GEL, MMP, AAL, CCL, SAVE, and GNKShould you be buying Provexis stock or one of its competitors? The main competitors of Provexis include Alkemy Capital Investments (ALK), CloudCoCo Group (CLCO), Iconic Labs (ICON), 22532 (PAA.L) (PAA), Greka Engineering & Technology (GEL), Marwyn Management Partners (MMP), Anglo American (AAL), Carnival Co. & (CCL), Savannah Energy (SAVE), and Greene King (GNK). These companies are all part of the "transportation" industry. Provexis vs. Alkemy Capital Investments CloudCoCo Group Iconic Labs 22532 (PAA.L) Greka Engineering & Technology Marwyn Management Partners Anglo American Carnival Co. & Savannah Energy Greene King Alkemy Capital Investments (LON:ALK) and Provexis (LON:PXS) are both small-cap financial services companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations. Does the media refer more to ALK or PXS? In the previous week, Alkemy Capital Investments' average media sentiment score of 0.00 equaled Provexis'average media sentiment score. Company Overall Sentiment Alkemy Capital Investments Neutral Provexis Neutral Does the MarketBeat Community prefer ALK or PXS? Alkemy Capital Investments received 92 more outperform votes than Provexis when rated by MarketBeat users. Likewise, 76.88% of users gave Alkemy Capital Investments an outperform vote while only 64.21% of users gave Provexis an outperform vote. CompanyUnderperformOutperformAlkemy Capital InvestmentsOutperform Votes15376.88% Underperform Votes4623.12% ProvexisOutperform Votes6164.21% Underperform Votes3435.79% Which has more risk & volatility, ALK or PXS? Alkemy Capital Investments has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Provexis has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Which has stronger valuation & earnings, ALK or PXS? Provexis has higher revenue and earnings than Alkemy Capital Investments. Provexis is trading at a lower price-to-earnings ratio than Alkemy Capital Investments, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkemy Capital InvestmentsN/AN/A-£1.29M-£14.59-7.18Provexis£846.98K17.18-£619.15K-£0.03-23.50 Is ALK or PXS more profitable? Alkemy Capital Investments has a net margin of 0.00% compared to Provexis' net margin of -73.10%. Alkemy Capital Investments' return on equity of 181.08% beat Provexis' return on equity.Company Net Margins Return on Equity Return on Assets Alkemy Capital InvestmentsN/A 181.08% -258.00% Provexis -73.10%-68.68%-56.14% Do insiders & institutionals hold more shares of ALK or PXS? 1.5% of Alkemy Capital Investments shares are held by institutional investors. Comparatively, 7.9% of Provexis shares are held by institutional investors. 43.7% of Alkemy Capital Investments shares are held by company insiders. Comparatively, 21.6% of Provexis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAlkemy Capital Investments beats Provexis on 7 of the 12 factors compared between the two stocks. Get Provexis News Delivered to You Automatically Sign up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PXS vs. The Competition Export to ExcelMetricProvexisDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£14.55M£2.23B£5.56B£2.56BDividend Yield5.06%2.92%5.11%4.97%P/E Ratio-23.503.9022.51132.30Price / Sales17.18539.40395.68227,040.56Price / CashN/A10.2538.1828.13Price / Book72.286.636.774.54Net Income-£619,153.31£20.70B£3.22B£5.84B7 Day Performance12.73%1.25%1.45%2.97%1 Month Performance40.91%2.56%3.97%9.00%1 Year PerformanceN/A92.55%16.14%114.85% Provexis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PXSProvexisN/AGBX 0.62+8.2%N/A-4.6%£14.55M£846,984.38-23.504Gap UpALKAlkemy Capital InvestmentsN/AGBX 109+1.4%N/A+18.9%£9.61MN/A-7.4725,500Gap UpCLCOCloudCoCo GroupN/AGBX 0.12-11.1%N/A-79.7%£864,000.00£27.84M-0.41125Gap DownICONIconic LabsN/AN/AN/AN/A£586,000.00£600,855.00-15.003Gap UpHigh Trading VolumePAA22532 (PAA.L)N/AN/AN/AN/A£0.00N/A0.004,100Gap UpHigh Trading VolumeGELGreka Engineering & TechnologyN/AN/AN/AN/A£0.00N/A0.002,110MMPMarwyn Management PartnersN/AN/AN/AN/A£0.00N/A0.001,660AALAnglo American2.0787 of 5 starsGBX 2,155+2.7%GBX 2,698.33+25.2%-23.0%£32.77B£36.94B-19.84129,700CCLCarnival Co. &N/AGBX 1,254.50-2.2%N/A+15.3%£22.67B£32.78B11.3740,000News CoverageSAVESavannah EnergyN/AGBX 7.25+2.1%N/AN/A£9.51B£18.46B-4.7011,100Gap UpGNKGreene KingN/AN/AN/AN/A£2.63B£2.22B21.941,010High Trading Volume Related Companies and Tools Related Companies Alkemy Capital Investments Alternatives CloudCoCo Group Alternatives Iconic Labs Alternatives 22532 (PAA.L) Alternatives Greka Engineering & Technology Alternatives Marwyn Management Partners Alternatives Anglo American Alternatives Carnival Co. & Alternatives Savannah Energy Alternatives Greene King Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:PXS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provexis plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Provexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
